Liver disease including history of viral hepatitis B or C, evidence of cirrhosis, chronic active or persistent hepatitis
Known history of chronic active hepatitis or liver cirrhosis (if suspected by laboratory studies, should be confirmed by liver biopsy).
EXCLUSION CRITERIA FOR SECOND-LINE THERAPY: Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patient’s liver function tests fall within the parameters
EXCLUSION CRITERIA FOR THIRD-LINE THERAPY: Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patient’s liver function tests fall within the parameters
Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
Active liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
Known pre-existing liver disease (e.g. cirrhosis, chronic hepatitis B or C, nonalcoholic steatohepatitis, sclerosing cholangitis)
Idelalisib\r\n* Ongoing drug-induced liver injury, chronic active hepatitis C (hepatitis C virus [HCV]), chronic active hepatitis B (hepatitis B virus [HBV]), alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, portal hypertension, or history of autoimmune hepatitis\r\n* Ongoing symptomatic pneumonitis\r\n* Ongoing inflammatory bowel disease or autoimmune colitis\r\n* Ongoing cytomegalovirus (CMV) infection, treatment, or prophylaxis within the past 28 days prior to the screening test for active CMV\r\n* History of serious allergic reaction including anaphylaxis and epidermal necrolysis
Pre-existing liver diseases (i.e., cirrhosis, chronic hepatitis B or C, nonalcoholic steatohepatitis, and sclerosing cholangitis, etc.)
No evidence of chronic active hepatitis or cirrhosis
Evidence of acute or chronic active hepatitis or cirrhosis
No evidence of chronic active hepatitis or cirrhosis
Known history of drug-induced liver injury, chronic active hepatitis B virus (HBV), chronic active hepatitis C virus (HCV), alcoholic liver disease, non-alcoholic steatohepatitis, cirrhosis of the liver, portal hypertension, primary biliary cirrhosis, or ongoing extrahepatic obstruction caused by cholelithiasis
Pre-existing liver diseases (i.e. cirrhosis, chronic hepatitis B or C, nonalcoholic steatohepatitis, sclerosing cholangitis)
Known clinically significant liver disease defined as ongoing drug-induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, portal hypertension, or history of autoimmune hepatitis.
Ongoing drug-induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), HIV, alcoholic liver disease, non-alcoholic steatohepatitis, cirrhosis of the liver, or portal hypertension
Active liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
Patients with liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis
History of liver disease, such as cirrhosis or chronic active hepatitis B and C
Patient has known chronic liver disease, e.g. diagnosis of chronic active hepatitis or cirrhosis
Active systemic hepatitis infection requiring treatment (carriers of hepatitis virus are permitted to enter the study), of any type or known acute or chronic liver disease including cirrhosis
Pre-existing liver diseases (i.e., cirrhosis, chronic hepatitis B or C, nonalcoholic steatohepatitis, and sclerosing cholangitis, etc.)
Known significant chronic liver disease, such as cirrhosis or active hepatitis (potential participants who test positive for hepatitis B surface antigen or hepatitis C antibodies are allowed provided they do not have active disease requiring antiviral therapy)
Patients must not have liver disease such a cirrhosis, chronic active hepatitis or chronic persistent hepatitis
known active or symptomatic viral hepatitis, chronic liver disease or liver cirrhosis;
Patients with liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis, or patients with defined elevated ALT/ AST/ Bilirubin.
Clinically confirmed diagnosis of HCC according to American Association for the Study of Liver Diseases (AASLD) criteria, including cirrhosis of any etiology or with chronic hepatitis B or C infection criteria
Known chronic liver disease, autoimmune hepatitis, or sclerosing cholangitis
Concomitant diseases/conditions: cardiac disease, immunodeficiency, chronic active hepatitis or cirrhosis, uncontrolled infection, bowel obstruction, any other major illness
Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
Patients must not have known liver disease such as cirrhosis, decompensated liver disease, active or chronic hepatitis
Pregnant or nursing females 2. HIV or HTLV-1/2 seropositivity 3. Known history of myelodysplasia 4. Known history of chronic active hepatitis or liver cirrhosis (if suspected by laboratory studies, should be confirmed by liver biopsy).
Active or severe liver disease (acute or chronic hepatitis, cirrhosis)
No evidence of chronic active hepatitis or cirrhosis
Active liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
Known hepatitis B or hepatitis C infection or liver cirrhosis
Any severe and/or uncontrolled medical conditions or other conditions that, in the treating physician’s opinion, could adversely impact their ability to participate in the study; NOTE: patients on chronic oxygen therapy, those with liver disease such as cirrhosis, chronic hepatitis or chronic persistent hepatitis, or uncontrolled infections will be excluded
Liver disease such as chronic cirrhosis, active hepatitis or chronic persistent hepatitis
EXPANSION COHORT ONLY: Liver disease such as chronic cirrhosis, active hepatitis or chronic persistent hepatitis
d. Liver disease such as cirrhosis of the liver, decompensated liver disease, chronic active hepatitis needing anti-viral therapy
Active or chronic hepatitis B or hepatitis C as demonstrated by hepatitis B surface antigen positivity and/or anti- hepatitis C virus positivity, respectively. Patients with clinically active or chronic liver disease, including liver cirrhosis of Child-Pugh class C, are also excluded.
Patient with known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis)
Serious concurrent medical conditions including: serious heart disease, heart conduction abnormalities, persistent infection, uncontrolled psychiatric illness, liver cirrhosis, chronic liver disease, active or symptomatic viral hepatitis, any other condition that may place the subject at an increased risk or confound the results of the study.
Ongoing drug-induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension.
Ongoing drug-induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension would be exclusion for idelalisib therapy but ibrutinib would be an option
Prior history of chronic liver disease (eg, chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemachromatosis, non-alcoholic steatohepatitis [NASH]).
Ongoing drug-induced liver injury, active hepatitis C, active hepatitis B , alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension.
Chronic hepatitis with advanced, decompensated hepatic disease or cirrhosis of the liver or history of chronic virus hepatitis or known viral hepatitis carrier (patient recovered from hepatitis A will be allowed to enter the study)
Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patient’s liver function tests fall within the parameters set
Known history of drug-induced liver injury, chronic active hepatitis B infection, chronic active hepatitis C infection, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, ongoing extrahepatic obstruction caused by stones, cirrhosis of the liver, or portal hypertension
Pre-existing liver disease (e.g. cirrhosis, chronic hepatitis B or C, nonalcoholic steatohepatitis, sclerosing cholangitis)
Ongoing drug-induced liver injury, chronic active Hepatitis C Virus (HCV), chronic active Hepatitis B Virus (HBV), HIV, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension
Cirrhosis or chronic active/persistent hepatitis
Known significant chronic liver disease, such as cirrhosis or active hepatitis (potential participants who test positive for hepatitis B surface antigen or hepatitis C antibodies are allowed provided they do not have active disease requiring antiviral therapy)
History of liver disease, such as cirrhosis or chronic active hepatitis B and C
No liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis.
Evidence of acute or chronic active hepatitis or cirrhosis
Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
Active liver disease including cirrhosis or hepatitis
Chronic active hepatitis or cirrhosis
No evidence of chronic active hepatitis or cirrhosis
Patients with a history of chronic active hepatitis, cirrhosis or hepatic encephalopathy
Non-surgical cohort only: pathology report from clinical liver biopsy (=< 3 months prior to pre-registration) demonstrates no histologic abnormalities associated with chronic hepatitis, steatohepatitis, fibrosis, or cirrhosis
Acute or chronic liver disease, evidence of hepatitis (infectious or autoimmune), cirrhosis or portal hypertension
Known chronic active hepatitis or cirrhosis
Severe liver disease (e.g. cirrhosis, non-alcoholic steatohepatitis, sclerosing cholangitis)
Positive serology for hepatitis C (HC) defined as a positive test for HC antibody (HepC Ab), in which case reflexively perform an HC recombinant immunoblot assay (RIBA) or hepatitis C viral load to confirm the result; if the confirmatory test is negative the subject will be eligible
Positive serology for hepatitis C (HC) defined as a positive test for hepatitis C antibody (HCAb), in which case reflexively perform a HC recombinant immunoblot assay (RIBA) on the same sample to confirm the result
Positive serology for hepatitis C (HC) defined as a positive test for hepatitis C antibody (HCAb) and confirmed by HC recombinant immunoblot assay (RIBA) or hepatitis C virus (HCV) ribonucleic acid (RNA) viral load
Positive serology for hepatitis C (HC) defined as a positive test for hepatitis C antibody (HCAb), in which case reflexively perform a hepatitis C virus (HCV) PCR to confirm the result
Positive serology for hepatitis C (HC) defined as a positive test for HBcAb, in which case reflexively perform a HC recombinant immunoblot assay (RIBA) on the same sample to confirm the result
Positive serology for hepatitis C (HC) defined as a positive test for HC antibody (Ab) if confirmed by HC recombinant immunoblot assay (RIBA) immunoblot assay (for positive HCAb reflexively perform a HC RIBA immunoblot assay on the same sample)
Positive serology for hepatitis C (HC) defined as a positive test for hepatitis C antibody (HCAb), in which case reflexively perform a HC radioimmunoblotting assay (RIBA) immunoblot assay on the same sample to confirm the result
Positive serology for hepatitis C (HC) defined as a positive test for hepatitis C antibody (HCAb)
Active hepatitis C infection; if positive serology for hepatitis C (HC) defined as a positive test for hepatitis C virus antibody (HCAb), HC quantitative polymerase chain reaction (PCR) will be performed; if PCR is positive the subject will be excluded
Positive serology for hepatitis C (HC) defined as a positive test for hepatitis C antibody (HCAb)
Positive hepatitis C serology or active hepatitis B infection; chronic asymptomatic viral hepatitis is allowed
Positive hepatitis B or C serology.
Positive serology for hepatitis B or hepatitis C or known HIV infection
Patient with active Hepatitis B or C determined by serology and/or NAAT.
PART I: Negative serology for hepatitis B and C unless the result is consistent with prior vaccination or prior infection with full recovery
PART II: Negative serology for hepatitis B and C unless the result is consistent with prior vaccination or prior infection with full recovery
Positive serology for HIV or hepatitis C
Positive serology for hepatitis B defined by a positive test for HBsAg
Has a known prior history of viral hepatitis (B or C) as demonstrated by positive serology (presence of antigens) or have an uncontrolled infection requiring treatment
Patients with positive hepatitis serology that is definitive of active disease.
Patients with chronic active hepatitis or cirrhosis. If positive hepatitis serology, the study chair may deem the patient eligible based on the results of liver biopsy.
Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology
Active hepatitis B or C determined by serology and/or nucleic acid testing (NAT)
Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology
Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology
Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology
Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology
Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients who either show chronic hepatitis C or positive hepatitis C serology
Has a prior history of viral hepatitis (B or C) as demonstrated by positive serology (presence of antigens) or have an uncontrolled infection requiring treatment. Participants with a known prior history of hepatitis B or C may be eligible pending agreement with the sponsor.
Positive hepatitis C serology or active hepatitis B infection
Patients with chronic active hepatitis or cirrhosis; if positive hepatitis serology, the study chair may deem the patient eligible based on the results of liver biopsy
Patients with positive serology for hepatitis C are NOT eligible
Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology
Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology.
Negative hepatitis C serology
Known positive serology for hepatitis B (unless due to vaccination or passive immunization due to immunoglobulin therapy)
Known positive serology for hepatitis C (unless due to immunoglobulin therapy)
Hepatitis B, hepatitis C, and human immunodeficiency virus (HIV) serology-positive (or known history of HIV seropositive status) participants are ineligible; hepatitis B, hepatitis C, and HIV serology-positive individuals were excluded from the pivotal pembrolizumab clinical trial in melanoma, so safety of this drug in this setting is unknown
Positive hepatitis C serology or active hepatitis B infection
Patients who have a prior history of viral hepatitis (B or C) as demonstrated by positive serology (presence of antigens) or have an uncontrolled infection requiring treatment are not eligible
Active hepatitis A, B or C infection\r\n* Hepatitis A serology is not required for normal liver function
Known positive hepatitis C serology or active hepatitis B infection – chronic asymptomatic viral hepatitis is allowed
positive hepatitis B and/or C serology.
Positive serology (unless due to vaccination or passive immunization due to Ig therapy) for hepatitis B
Positive serology for hepatitis C based on test at screening.
Positive test results for hepatitis C (hepatitis C virus [HCV] antibody serology testing)
Negative serology for active hepatitis B and C for anakinra arm. Patients with positive serology for hepatitis B might eligible if they are willing to take lamivudine preventive therapy.
Patient must not have a history of positive hepatitis C serology
Hepatitis B carrier status history of hepatitis B virus (HBV) or positive serology; a patient is considered as HBV carrier or to have (had) HBV infection in case of: \r\n* Unimmunized and hepatitis B surface antigen (HBsAg) and/or anti-HBs antibody and/or anti- HBc antibody positive,\r\n* Immunized and HBsAG and/or anti-HBc antibody positive\r\n** Important note: for the phase III trial, a patient without a known history of hepatitis B could be randomized in the study if the serology results are not available at the time of the randomization; however, if the serology results are positive or not available at day 6 (the first day would be due to receive rituximab, if so randomized), the patient must be withdrawn from the study whatever the allocated treatment arm; the data center must be informed immediately; for the phase II trial, the hepatitis B serology results must be available before registration; in each case indicating a carrier status or history for hepatitis B infection, the patients must not receive rituximab, and therefore must not be included in the rituximab trials on any treatment arm; in case of high-risk patients, the recommendation is to treat these patients with the standard LMB regimen corresponding to the patient prognostic group; in the case of PMLBL the physician is left to choose the most appropriate therapy
A positive hepatitis C serology is an exclusion criterion
Hepatitis B carrier status history of HBV or positive serology.
Positive serology for Hepatitis B
Hepatitis B (HBV)-positive serology and is receiving interferon therapy or has liver function test results outside the parameters of study inclusion criteria. Other antiviral therapies are permitted if at a stable dose for at least 4 weeks.
Patients with chronic active hepatitis or cirrhosis; if positive hepatitis serology, the study chair may deem the patient eligible based on the results of liver biopsy
Positive serology (unless due to vaccination or passive immunization due to Ig therapy) for hepatitis B
Positive serology for hepatitis C based on test at screening.
Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology
Positive hepatitis serology
Positive hepatitis C serology
Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology
Positive serology for HTLV 1 or 2.
Patient with active Hepatitis B or C determined by serology and/or nucleic acid amplification tests (NAAT)
